Novo Nordisk completes PhIII hemophilia trial with positive results

Emily Mullin In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients. FierceBiotech News

CytRx dumps failed IIb trial for lung cancer, focuses on aldoxorubicin

John Carroll CytRx has decided to dump a Phase IIb lung cancer study for the number-two drug program in the pipeline after the monitoring committee concluded that the trial was unlikely ...

Seaside Therapeutics fails to achieve main goal in major trial in autism

Ryan McBride Seaside Therapeutics missed the main target of a midstage trial of its lead drug STX209 in patients with autism spectrum disorder (ASD), yet benefits of treatment observed ...

Merck wins bellwether Fosamax femur-fracture trial

Tracy Staton The jury in the latest Fosamax trial has spoken, and it spoke for Merck ($ MRK). In a federal court in New Jersey, the panel determined that plaintiff Bernadette Glynn's ...

NIH stops HIV vaccine trial after immunizations fail

Emily Mullin The federal government has put the brakes on the largest and most advanced study of a vaccine against HIV infection after an independent data and safety monitoring board ...

Gilead keeps lead in hep C race after rivals post key trial results

Ryan McBride After delivering data from multiple rounds of trials on all-oral combos against hepatitis C, pharma runners appear to be making progress with new therapies that could ...

India’s clinical trial industry shrivels in wake of safety controversy

John Carroll   With its huge population and a savvy mix of drug development experts on the ground in India, analysts had once estimated that the clinical trial business on the ...

Civitas Parkinson’s drug improves motor fluctuations in Phase II trial

Emily Mullin Alkermes ($ ALKS) spinout Civitas Therapeutics today reported positive topline results from a Phase II clinical trial of its Parkinson's drug CVT-301, which ...

Roche sees another Rituxan biosimilar trial bite the dust

Ryan McBride Roche ($ RHHBY) faces one less potential copycat competitor to its blockbuster Rituxan franchise. The South Korea-based biotech Celltrion has nixed late-stage development ...

Merck kept mum on Fosamax’s fracture risks, trial lawyer says

Tracy Staton Image courtesy of NIH Did Merck know about increased fracture risk in Fosamax patients years before the osteoporosis treatment hit the market? A plaintiff’s ...
Page 12 of 12« First...89101112
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS